EMAIL ALERTS Sign up to receive e-mail alerts whenever ImClone Systems posts new information to the site. Just enter your e-mail address and click Submit.		Corporate Profile ImClone Systems is dedicated to developing and commercializing novel therapeutic products in the field of oncology. Our efforts have resulted in a broad spectrum of innovative product candidates with potential application in multiple tumor types. As a member of the oncology community, we are committed to providing treatments to meet the unmet needs of cancer patients. To fulfill this commitment, ImClone Systems fosters integration of the principles of teamwork and scientific integrity into all facets of the Company’s activities. We believe that these values will benefit patients, physicians, and our employees while creating value for our shareholders. Financial Information Reconciliation of Non-GAAP Operating Income to Operating Income Prepared in Accordance with GAAP Recent News More >> Date Title   09/23/09 Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress 09/21/09 Lilly Names New Business Leaders 09/21/09 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 07/22/09 Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs Upcoming Events More >> There are currently no events scheduled. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Company Overview | Clinical Programs | Research | News | Careers | Product Support Program
Copyright © 2009 ImClone LLC. All rights reserved.